INVESTIGADORES
ALONSO Daniel Fernando
artículos
Título:
NGcGM3 ganglioside: a privileged target for cancer vaccines
Autor/es:
LE FERNANDEZ; MR GABRI; M GUTHMANN; RE GOMEZ; S GOLD; DE GOMEZ; DF ALONSO
Revista:
CLINICAL AND DEVELOPMENTAL IMMUNOLOGY
Editorial:
HINDAWI PUBLISHING CORPORATION
Referencias:
Año: 2010 vol. 2010 p. 814397 - 814397
ISSN:
1740-2522
Resumen:
Active specific immunotherapy is a promising field in cancer research.
N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received
attention as a privileged target for cancer therapy. Many clinical
trials have been performed with the anti-NGc-containing gangliosides
anti-idiotype monoclonal antibody racotumomab (formerly known as 1E10)
and the conjugated NGcGM3/VSSP vaccine for immunotherapy of melanoma,
breast, and lung cancer. The present paper examines the role of
NGc-gangliosides in tumor biology as well as the available preclinical
and clinical data on these vaccine products. A brief discussion on the
relevance of prioritization of cancer antigens in vaccine development is
also included.